Supplemental financial information (Tables)

9 Months Ended

Sep. 30, 2018

Supplemental financial information

Schedule of cash, cash equivalents and restricted cash

The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the balance sheets that sum to the total of the same such amounts shown in the statements of cash flows (amounts in thousands).

	As of		As of
	September 30,		December 31,
	2018		2017
Cash and cash equivalents	$	165,578	$	92,136
Short-term and long-term restricted cash		491		473
Total cash, cash equivalents, and restricted cash shown in the statements of cash flows	$	166,069	$	92,609

Schedule of prepaid expenses and other current assets

Prepaid expenses and other current assets consist of the following (in thousands):

	As of		As of
	September 30,		December 31,
	2018		2017
Prepaid clinical	$	173	$	1,718
Prepaid insurance		791		137
Other prepaid expenses and current assets		205		105
Total prepaid expenses and other current assets	$	1,169	$	1,960

Schedule of accrued expenses and other current liabilities

Accrued expenses and other current liabilities consist of the following (in thousands):

	As of		As of
	September 30,		December 31,
	2018		2017
Employee-related expenses	$	2,056	$	1,435
Development costs and sponsored research		1,805		737
Clinical trials		2,282		69
Other		322		594
Total accrued expenses and other current liabilities	$	6,465	$	2,835